Journal of International Oncology››2022,Vol. 49››Issue (7): 447-448.doi:10.3760/cma.j.cn371439-20210709-00086
Received:2021-07-09Revised:2022-01-12Online:2022-07-08Published:2022-09-19
"
"
"
| [1] | Platoff RM, Kellish AS, Hakim A, et al. Simple versus radical resection for duodenal adenocarcinoma: a propensity score matched analysis of national cancer database[J]. Am Surg, 2021, 87(2): 266-275. DOI: 10.1177/0003134820951432. doi:10.1177/0003134820951432 |
| [2] | 边志民. 恶性肠梗阻的治疗[J]. 中国医师杂志, 2020, 22(11): 1601-1605. DOI: 10.3760/cma.j.cn431274-20201026-01446. doi:10.3760/cma.j.cn431274-20201026-01446 |
| [3] | Pedersen K, Foster N, Overman M, et al. O-007-ZEBRA: an ACCRU/IRCI multicenter phase 2 study of pembrolizumab in patients with advanced small bowel adenocarcinoma (SBA)[J]. Ann Oncol, 2019, 30(Suppl-4): iv128. DOI: 10.1093/annonc/mdz154.006. doi:10.1093/annonc/mdz154.006 |
| [4] | Overman MJ, Lonardi S, Wong KYM, et al. Durable clinical be-nefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer[J]. J Clin Oncol, 2018, 36(8): 773-779. DOI: 10.1200/JCO.2017.76.9901. doi:10.1200/JCO.2017.76.9901 |
| [5] | Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase Ⅱ KEYNOTE-158 study[J]. J Clin Oncol, 2020, 38(1): 1-10. DOI: 10.1200/JCO.19.02105. doi:10.1200/JCO.19.02105pmid:31682550 |
| [6] | Zhou C, Chen G, Huang Y, et al. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial[J]. Lancet Respir Med, 2021, 9(3): 305-314. DOI: 10.1016/S2213-2600(20)30365-9. doi:10.1016/S2213-2600(20)30365-9 |
| [7] | Xu J, Shen J, Gu S, et al. Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a nonrandomized, open-label, phase Ⅱ trial[J]. Clin Cancer Res, 2021, 27(4): 1003-1011. DOI: 10.1158/1078-0432.CCR-20-2571. doi:10.1158/1078-0432.CCR-20-2571 |
| [8] | Luo H, Lu J, Bai Y, et al. Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial[J]. JAMA, 2021, 326(10): 916-925. DOI: 10.1001/jama.2021.12836. doi:10.1001/jama.2021.12836 |
| [9] | 程传耀, 解智慧, 柴慧芳, 等. mFOLFOX6方案联合卡瑞利珠单抗对微卫星不稳定直肠癌患者免疫功能的影响[J]. 肿瘤基础与临床, 2021, 34(5): 410-413. DOI: 10.3969/j.issn.1673-5412.2021.05.012. doi:10.3969/j.issn.1673-5412.2021.05.012 |
| [10] | Chen J, Quan M, Chen Z, et al. Camrelizumab in advanced or metastatic solid tumour patients with DNA mismatch repair deficient or microsatellite instability high: an open-label prospective pivotal trial[J]. J Cancer Res Clin Oncol, 2020, 146(10): 2651-2657. DOI: 10.1007/s00432-020-03251-5. doi:10.1007/s00432-020-03251-5 |
| [11] | Waterhouse DM, Garon EB, Chandler J, et al. Continuous versus 1-year fixed-duration nivolumab in previously treated advanced non-small-cell lung cancer: CheckMate 153[J]. J Clin Oncol, 2020, 38(33): 3863-3873. DOI: 10.1200/JCO.20.00131. doi:10.1200/JCO.20.00131 |
| No related articles found! |
| Viewed | ||||||
| Full text |
|
|||||
| Abstract |
|
|||||
